首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1542440

全球癌症惡病質市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Cancer Cachexia Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2032 年，全球癌症惡病質市場的市場規模將從 2023 年的 28.4 億美元達到近 45 億美元，2024-2032 年研究期間複合年成長率為 5.22%。

癌症惡病質是一種複雜的代謝症候群，其特徵是癌症患者嚴重體重減輕、肌肉萎縮和食慾下降。與單純的營養不良不同，惡病質是由潛在的癌症相關因素引起的，涉及全身性發炎、代謝改變和蛋白質分解增加。這種情況會嚴重影響患者的生活品質，使治療方案複雜化，並導致預後不良。此症候群的病理生理學涉及腫瘤衍生因子與宿主代謝過程之間的相互作用，導致體重和力量逐漸喪失。有效管理這種症候群對於改善患者預後和提高癌症治療效果至關重要。治療通常包括營養支持、抗發炎藥物和針對潛在疾病機制的介入措施。解決惡病質對於全面的癌症護理和改善受影響患者的整體健康至關重要。

市場動態

全球癌症盛行率不斷上升，這反過來又推動了對惡病質等相關併發症的有效管理策略的需求。隨著癌症發生率的上升，對治療惡病質的療法的需求變得更加迫切，從而創造了巨大的癌症惡病質市場潛力。另一個促進因素是人們越來越認知到癌症惡病質是一種需要專門治療的獨特而嚴重的疾病。醫療保健專業人員和患者對惡病質對癌症結果影響的認知不斷提高，這推動了對有效治療方案的需求。這種認知導致更多的研究和開發工作集中在了解惡病質的潛在機制和開發有針對性的治療方法。針對惡病質涉及的代謝和發炎途徑的新療法的開發提供了巨大的機會。藥物開發和營養干預的創新為新的治療選擇打開了大門，可以改善患者的治療結果。此外，個人化醫療的進步允許根據個別患者的情況採取更量身定做的方法來管理惡病質。製藥公司、研究機構和臨床組織之間的合作推動了成長。這些合作關係對於進行臨床試驗、推進研究以及將新療法推向市場至關重要。然而，有限的治療選擇和高昂的成本可能會阻礙癌症惡病質市場的成長。有效療法的稀缺性以及與開發和獲得惡病質治療相關的經濟負擔可能會限制市場擴張並影響患者獲得護理的機會。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對癌症惡病質全球市場的每個細分市場進行了包容性評估。癌症惡病質產業的成長和趨勢為本研究提供了整體方法。

市場區隔

癌症惡病質市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

透過治療學

黃體素
皮質類固醇
聯合療法
其他

按作用機制

食慾刺激器
減肥穩定劑
其他

按配銷通路

醫院商店
零售藥局
網路藥局

區域分析

本節涵蓋區域展望，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲癌症惡病質市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。癌症惡病質市場的主要參與者包括 Aeterna Zentaris Inc.、Alder BioPharmaceuticals Inc.、Aphios Corporation、Eli Lilly And Company、GlxInc.、Helsinn Group、Merck & Co. Inc.、Novartis AG、Bristol-Myers Squibb Company、XBiotech公司。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：癌症 Cachexia 公司的競爭格局

癌症惡病質市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Aeterna Zentaris Inc.

公司概況
公司收入
產品
最新動態

Alder BioPharmaceuticals Inc.

公司概況
公司收入
產品
最新動態

Aphios Corporation

公司概況
公司收入
產品
最新動態

Eli Lilly And Company

公司概況
公司收入
產品
最新動態

GlxInc.

公司概況
公司收入
產品
最新動態

Helsinn Group

公司概況
公司收入
產品
最新動態

Merck & Co. Inc.

公司概況
公司收入
產品
最新動態

Novartis AG

公司概況
公司收入
產品
最新動態

Bristol-Myers Squibb Company

公司概況
公司收入
產品
最新動態

XBiotech Inc

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11214594

The global demand for Cancer Cachexia Market is presumed to reach the market size of nearly USD 4.5 Billion by 2032 from USD 2.84 Billion in 2023 with a CAGR of 5.22% under the study period 2024-2032.

Cancer cachexia is a complex metabolic syndrome featuring severe weight loss, muscle wasting, and decreased appetite in cancer patients. Unlike simple malnutrition, cachexia is driven by underlying cancer-related factors and involves systemic inflammation, altered metabolism, and increased protein breakdown. This condition significantly impacts a patient's quality of life, complicates treatment regimens, and contributes to poor prognoses. The pathophysiology of this syndrome involves interactions between tumor-derived factors and the host's metabolic processes, leading to the progressive loss of body mass and strength. Effective management of this syndrome is critical for enhancing patient outcomes & enhancing the efficacy of cancer therapies. Treatments often include nutritional support, anti-inflammatory agents, and interventions targeting the underlying disease mechanisms. Addressing cachexia is essential for comprehensive cancer care and improving the overall well-being of affected patients.

MARKET DYNAMICS

The increasing prevalence of cancer globally, which in turn drives demand for effective management strategies for associated complications like cachexia. As the incidence of cancer rises, the need for therapies addressing cachexia becomes more critical, creating significant cancer cachexia market potential. Another driver is the growing recognition of cancer cachexia as a distinct and serious condition requiring specialized treatment. The increased awareness among healthcare professionals & patients about the impact of cachexia on cancer outcomes is fuelling the demand for effective therapeutic options. This awareness is leading to more research and development efforts focused on understanding the underlying mechanisms of cachexia and developing targeted treatments. The development of novel therapies targeting the metabolic and inflammatory pathways involved in cachexia presents substantial opportunities. Innovations in drug development and nutritional interventions open the door to new treatment options that can improve patient outcomes. Additionally, the advancement of personalized medicine allows for more tailored approaches to managing cachexia based on individual patient profiles. Collaborations between pharmaceutical companies, research institutions, and clinical organizations drive growth. These partnerships are essential for conducting clinical trials, advancing research, and bringing new treatments to market. However, limited treatment options and high costs may hinder cancer cachexia market growth. The scarcity of effective therapies and the financial burden associated with developing and accessing cachexia treatments can restrict market expansion and affect patient access to care.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cancer Cachexia. The growth and trends of Cancer Cachexia industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cancer Cachexia market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapeutics

Progestogens
Corticosteroids
Combination Therapies
Others

By Mechanism of Action

Appetite Stimulators
Weight Loss Stabilizers
Others

By Distribution Channel

Hospital Stores
Retail Pharmacy Stores
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cancer Cachexia market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cancer Cachexia market include Aeterna Zentaris Inc., Alder BioPharmaceuticals Inc., Aphios Corporation, Eli Lilly And Company, GlxInc., Helsinn Group, Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, XBiotech Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CANCER CACHEXIA - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapeutics
- 3.7.2 Market Attractiveness Analysis By Mechanism of Action
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY THERAPEUTICS

5.1. Overview By Therapeutics
5.2. Historical and Forecast Data Analysis By Therapeutics
5.3. Progestogens Historic and Forecast Sales By Regions
5.4. Corticosteroids Historic and Forecast Sales By Regions
5.5. Combination Therapies Historic and Forecast Sales By Regions
5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY MECHANISM OF ACTION

6.1. Overview By Mechanism of Action
6.2. Historical and Forecast Data Analysis By Mechanism of Action
6.3. Appetite Stimulators Historic and Forecast Sales By Regions
6.4. Weight Loss Stabilizers Historic and Forecast Sales By Regions
6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data Analysis By Distribution Channel
7.3. Hospital Stores Historic and Forecast Sales By Regions
7.4. Retail Pharmacy Stores Historic and Forecast Sales By Regions
7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CANCER CACHEXIA COMPANIES

9.1. Cancer Cachexia Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF CANCER CACHEXIA INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Aeterna Zentaris Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Alder BioPharmaceuticals Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Aphios Corporation
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Eli Lilly And Company
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. GlxInc.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Helsinn Group
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Merck & Co. Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Novartis AG
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Bristol-Myers Squibb Company
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. XBiotech Inc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments